Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

Max Kates, Andrés Matoso, Woonyoung Choi, Alexander S. Baras, Marcus J. Daniels, Kara A. Lombardo, Aaron Brant, Nina Mikkilineni, David J. McConkey, Ashish M. Kamat, Robert S. Svatek, Sima P. Porten, Joshua J. Meeks, Seth P. Lerner, Colin P. Dinney, Peter C. Black, James M. McKiernan, Chris Anderson, Charles G. Drake, Trinity J. BivalacquaClinical 2019 · DOI

Abstract

One mechanism of BCG failure may be adaptive immune resistance. Baseline tumor PD-L1 expression predicts an unfavorable response to BCG and if validated, could be used to guide therapeutic decisions.
BibTeX
@inproceedings{kates2019adaptive,
  author = {Max Kates and Andrés Matoso and Woonyoung Choi and Alexander S. Baras and Marcus J. Daniels and Kara A. Lombardo and Aaron Brant and Nina Mikkilineni and David J. McConkey and Ashish M. Kamat and Robert S. Svatek and Sima P. Porten and Joshua J. Meeks and Seth P. Lerner and Colin P. Dinney and Peter C. Black and James M. McKiernan and Chris Anderson and Charles G. Drake and Trinity J. Bivalacqua},
  title = {{Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials}},
  booktitle = {Clinical},
  year = {2019},
  doi = {10.1158/1078-0432.ccr-19-1920},
}

Loading related content...

Figure